只需1针!默沙东Clesrovimab中国申报上市:有望改写RSV抗体疗法格局

药渡
06 Apr

来源:药渡撰文:Pharmadeep编辑:活力哈哈2025年4月2日,默沙东抗RSV单抗药物Clesrovimab注射液在华申报上市并拟纳入优先审评,这一进展将为中国新生儿和婴儿群体带来首个“单次注射、长效防护”的呼吸道合胞病毒(RSV)预防方案。图片来源:国家药品监督管理局Clesrovimab核心优势:从“被动免疫”到“长效便捷”1. 单次给药,剂量统一Clesrovimab是全球首款无需根据...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10